Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Rating of "Buy" from Brokerages

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) has earned an average rating of "Buy" from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. Ten analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $27.89.

CNTA has been the subject of a number of research analyst reports. Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 price target for the company. Morgan Stanley reissued an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price on the stock. Guggenheim reaffirmed a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price objective for the company.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 14,656 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $12.29, for a total transaction of $180,122.24. Following the transaction, the chief executive officer now directly owns 261,361 shares of the company's stock, valued at $3,212,126.69. The trade was a 5.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Arjun Goyal acquired 44,939 shares of Centessa Pharmaceuticals stock in a transaction on Thursday, May 15th. The shares were bought at an average price of $12.24 per share, for a total transaction of $550,053.36. Following the purchase, the director now owns 44,939 shares of the company's stock, valued at $550,053.36. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 152,398 shares of company stock valued at $1,945,852. Insiders own 7.09% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in Centessa Pharmaceuticals by 40.1% in the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company's stock worth $3,189,000 after buying an additional 54,482 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Centessa Pharmaceuticals by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company's stock worth $1,928,000 after acquiring an additional 14,494 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Centessa Pharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock worth $38,668,000 after acquiring an additional 6,000 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock valued at $959,000 after purchasing an additional 660 shares during the last quarter. Finally, Trexquant Investment LP grew its stake in Centessa Pharmaceuticals by 52.8% during the 4th quarter. Trexquant Investment LP now owns 261,184 shares of the company's stock valued at $4,375,000 after purchasing an additional 90,233 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Stock Performance

CNTA traded up $1.20 during trading on Friday, hitting $14.20. The stock had a trading volume of 1,411,051 shares, compared to its average volume of 724,203. The firm has a market capitalization of $1.90 billion, a P/E ratio of -7.85 and a beta of 1.48. The company has a debt-to-equity ratio of 0.28, a quick ratio of 14.37 and a current ratio of 14.37. Centessa Pharmaceuticals has a twelve month low of $8.46 and a twelve month high of $19.09. The company's 50-day moving average price is $12.72 and its 200 day moving average price is $14.79.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. On average, equities research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.